The Zhitong Finance App learned that Centinel Spine, a well-known US medical device manufacturer, disclosed in the US stock market initial public offering (IPO) filing on Wednesday local time that revenue for the first half of the year increased sharply by 42%. Centinel Spine's submission of an IPO application can be described as providing an observation sample for global investors focusing on medical devices that “technology commercialization, revenue growth, and profit improvement are progressing at the same time.”
For the global medical device sector, the investment significance of Centinel Spine's current IPO is mainly: segmented enterprises with clear clinical use, continuous commercialization capabilities, and profit base have the opportunity to obtain differentiated pricing; the final IPO issuance and valuation estimates and market subscription performance will test how high the market is willing to pay for the quality of growth dominated by this innovative medical device industry. Currently, the company has yet to complete the IPO issuance and final valuation.
According to information, the company's IPO filing comes at a time when the outlook for the global IPO market in the fall is uncertain. The rise in global bond yields, led by a surge in long-term US bond yields of 10 years or more, and the prospects for high interest rates in the context of global central banks fighting inflation have weakened investors' willingness to actively invest and prompted several large companies, including OpenAI and Anthropic, to postpone listing.
Prior to the IPO, it achieved a significant 42% increase in revenue and reversed losses strongly
The medical device company, headquartered in West Chester, Pennsylvania, achieved revenue of approximately US$85.2 million and net profit of approximately US$10.2 million in the six months to June 30; in comparison, revenue for the same period last year was US$60.1 million and net loss was approximately US$503 million.
Centinel Spine develops and manufactures artificial discs designed to preserve cervical and lumbar spine mobility, providing an alternative to spinal fusion surgery. Spinal fusion usually permanently removes the mobility of the segment being treated.
Fusion surgery uses bone grafting and is often fixed with screws, steel bars, etc., so that the adjacent vertebrae eventually grow into a firm bony whole; after successful fusion, the original relative movement between the two vertebrae disappears, but other unfused segments can still move.
Why might this in turn improve organizational function? This is because some diseased segments are already in a state of “pain as soon as they move, and the structure is unstable.” Fusion surgery reduces painful movements and restores stability at the cost of sacrificing this part of the activity; when there is nerve compression, it is also possible to reduce pressure at the same time. Patients may be more able to stand, walk, and complete daily activities due to reduced pain, although local flexibility is reduced. The degree of impact depends on the location, extent, and preexisting condition of the fusion, and not all patients will have the same effect. In contrast, the technical goal of an artificial disc is to relieve symptoms while trying to replace the diseased disc with a movable implant to preserve the mobility of this segment as much as possible. But retaining exercise doesn't mean an artificial disc is better for all patients.
According to the company, its prodisc platform has been used for more than 300,000 implants worldwide and has been supported by more than 590 peer-reviewed clinical papers.
IPOX Research Assistant Lukas Muehlbauer told the media: “One thing worth noting in the Centinel filing is that the company was able to achieve strong revenue growth while maintaining strong profits, which distinguishes it from many healthcare companies preparing to enter the open capital market.”
“At the same time, the company's focus on the single field of total disc replacement has created a risk of business concentration, causing it to face the impact of changes in medical expenses reimbursement policies and competitive technology to a certain extent.”
Centinel Spine plans to use the funds raised in this offering to repay debts and invest in sales infrastructure, patient education programs, and clinical trials.
According to information, Wall Street financial giants such as Morgan Stanley, Goldman Sachs, Piper Sandler, Canaccord Genuity, and BTIG acted as underwriters for this launch. The company plans to be listed on the New York Stock Exchange, and the stock code is proposed to be “CNTL.”
The company disclosed on October 7 that revenue for the first half of 2026 increased from 60.1 million US dollars to 85.2 million US dollars, an increase of about 42% over the previous year; net profit reached 10.2 million US dollars, and a loss of 503 million US dollars in the same period last year. Based on this calculation, the net interest rate increased from about -0.8% to 12.0%. The company plans to list on the New York Stock Exchange under the code “CNTL” to raise funds for debt repayment, sales system construction, patient education, and clinical trials. In a context where high interest rates and rising bond yields are suppressing global stock market valuation expansion and IPO demand, this combination makes it easier for investors to evaluate their commercial value based on existing income and profits.
How This Artificial Disc Pioneer Turns Technical Barriers Into Profit
Centinel Spine is a medical device company headquartered in West Chester, Pennsylvania, USA, focusing on total disc replacement (TDR). The core prodisc platform covers cervical and lumbar artificial discs. It aims to replace the diseased disc while retaining the activity of the treated segment, and provides treatment options other than spinal fusion for patients who meet the indications.
After the company sold the integrated business in 2023, it further focused on this field; according to company statistics, the ProDisc series has installed more than 300,000 copies worldwide, and more than 590 related articles have been published. Its commercial competitiveness is mainly based on the accumulation of cutting-edge implant design, long-term clinical evidence, approved indications, and more scalable physicians and sales channels.
The underlying logic behind the company's recent strong growth is that indications, doctor adoption, and sales coverage all drive product penetration. The US pharmaceutical regulator FDA approved ProDisc C Vivo and C SK for one or two adjacent cervical segments in October 2025, providing a product foundation for subsequent commercial expansion. However, the company's focus on the advantages of specialization brought by a single technology route also meant that reimbursement policies and alternative technology had a more direct impact on its valuation.
From the perspective of investment research, expanding the scope of applicable patients, increasing doctors' usage experience, and expanding sales networks may all drive an increase in implant revenue; if the new revenue can cover corresponding sales, R&D, and clinical investment, there are conditions to form a scale effect. This revenue increase coincided with loss reversal, which is a sign of profit improvement worth tracking, but the news information currently disclosed by the company is insufficient to attribute all of the profit improvements to operating leverage, nor to attribute all of the 42% increase to the approval of a certain product. For similar medical device-related companies around the world, more comparable indicators are growth in surgery and implant volume, product penetration rate, payment coverage, and continued profitability.
In terms of valuation, there is currently no confirmed IPO equity valuation. According to public information that can be verified so far, the company has not disclosed the issuance price range or number of shares issued; the IPO tracking agency listed about 100 million US dollars on the proposed fund-raising scale. It is not the company's valuation, and the final issuance scale is yet to be determined. The potential impact of the company's future valuation on the medical device sector mainly focuses on providing additional valuation references for “high-growth and profitable” specialty medical device type companies; this reference is more direct for innovators in artificial intervertebral discs and similar orthopedic creative medical devices.